Bladder Cancer Coverage from Every Angle

Monika Joshi, MD, on Findings on Chemoradiation With Durvalumab in Urothelial Carcinoma

Posted: Friday, July 8, 2022

Monika Joshi, MD, of Penn State Cancer Institute, discusses the ongoing phase II INSPIRE trial, which is investigating bladder-sparing chemoradiation with durvalumab as a new treatment strategy for stage III bladder cancer in the first prospective study designed for lymph node–positive disease alone. Dr. Joshi urges her colleagues to join the study.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.